Bioniche Life Sciences Inc. is a leading clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.
The Company is publicly traded on the Toronto Stock Exchange (TSX: BNC).
The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.
For recent media coverage of Bioniche Life Sciences Inc. click here >>
November 25, 2014
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC.
November 13, 2014
Bioniche Life Sciences Inc. Announces Results of Annual General Meeting of Shareholders SHAREHOLDERS
November 12, 2014
Bioniche Life Sciences Inc. Reports MCNA Update & First Quarter Results